1. Home
  2. IMC vs OBX Comparison

IMC vs OBX Comparison

Compare IMC & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IMC Rare Earths Ltd Ordinary Shares

IMC

IMC Rare Earths Ltd Ordinary Shares

N/A

Current Price

$10.72

Market Cap

728.3M

ML Signal

N/A

Logo Obsidian Therapeutics Inc. Common Stock

OBX

Obsidian Therapeutics Inc. Common Stock

N/A

Current Price

$14.00

Market Cap

861.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMC
OBX
Founded
2025
2015
Country
Brazil
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
728.3M
861.1M
IPO Year
2026
2026

Fundamental Metrics

Financial Performance
Metric
IMC
OBX
Price
$10.72
$14.00
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $39.00
AVG Volume (30 Days)
106.8K
★ 300.4K
Earning Date
11-10-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.80
$11.52
52 Week High
$12.00
$39.00

Technical Indicators

Market Signals
Indicator
IMC
OBX
Relative Strength Index (RSI) 63.90 47.42
Support Level $6.23 $11.84
Resistance Level $11.84 $19.97
Average True Range (ATR) 1.16 1.09
MACD 0.48 0.40
Stochastic Oscillator 73.33 56.78

Price Performance

Historical Comparison
IMC
OBX

About IMC IMC Rare Earths Ltd Ordinary Shares

IMC Rare Earths Ltd is a mineral exploration and development company engaged in the exploration, evaluation and development of minerals and metals in Brazil. Its main REE project is the Itarantim Project located in the States of Bahia and Minas Gerais, Brazil.

About OBX Obsidian Therapeutics Inc. Common Stock

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Share on Social Networks: